Pfizer Inc said on Friday that its experimental rheumatoid arthritis drug met the main goals of a late-stage clinical trial, a welcome boost for the world's largest drugmaker as it seeks new products to offset those that are losing patent protection.
49489
Pfizer arthritis drug meets main goals of trial
45298
Pfizer pulling leukemia drug called Mylotarg from US market
51486
Anti-cancer drug discovered by scientists in seaweed
138888
Research could improve cancer treatment
72746
Drug originally intended to lower
143153
Cardiac medical device shows promise in clinical trial
71114
Anakinra is relatively safe, modestly effective in rheumatoid arthritis
16512
Nexavar in Combination with Chemotherapy Shown to Extend...
138078
Eli Lilly completes final phase of biotechnology expansion
75564
Pfizer pays out to doctors, researchers
82505
Arthritis drug Vioxx not fit for sale
88639
ICON selected as Pfizer strategic partner
79889
Merck buys drug rival Schering-Plough
145835
Novocell announces non-exclusive drug discovery collaboration with Pfizer
141095
Natural medicine will reverse Rheumatoid Arthritis
169382
Research could increase the life of artificial joint implants
146799
Pfizer launches Twitter feed